BofA lowered the firm’s price target on Sanofi (SNY) to EUR 102 from EUR 115 and keeps a Buy rating on the shares. The firm, which calls the next 12 months “light on catalysts,” sees further amlitelimab data as “important,” but adds that it may need launch to “convince investors.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- US, UK expected to agree on zero-tariffs pharmaecuticals deal, UK Times says
- Sanofi’s Undervalued Stock and Growth Prospects Drive Buy Rating Despite Near-Term Challenges
- Sanofi’s Parisian HQ raided in French tax fraud probe, Le Monde reports
- Regeneron, Sanofi announce European Commission approval for Dupixent
- DarioHealth announces publication of study in JMIR on digital health platform